Trypanosomiasis, cardiomyopathy and the risk of ischemic stroke

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 5, 2010, Pages 717-728

  Carod Artal, Francisco Javier ^a  

^a Virgen de la Luz Hospital   (Spain)

Author keywords

African trypanosomiasis; American trypanosomiasis; Cardiomyopathy; Chagas disease; Sleeping sickness; Stroke

Indexed keywords

AMIODARONE; ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; EFLORNITHINE; MELARSOPROL; NIFURTIMOX; PENTAMIDINE; PLACEBO; PYRROLE DERIVATIVE; RAVUCONAZOLE; TISSUE PLASMINOGEN ACTIVATOR;

ABDOMINAL PAIN; AFRICA; AFRICAN TRYPANOSOMIASIS; AGRANULOCYTOSIS; ANOREXIA; ANTICOAGULANT THERAPY; BONE MARROW HYPOPLASIA; BRAIN DISEASE; BRAIN ISCHEMIA; CHAGAS DISEASE; DERMATITIS; ELECTROCARDIOGRAPHY; EMBOLISM; ENDOCRINE DISEASE; FEVER; GASTROINTESTINAL SYMPTOM; HEART ANEURYSM; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; INSOMNIA; LYMPHADENOPATHY; MIDDLE CEREBRAL ARTERY; NAUSEA AND VOMITING; NEURITIS; NEUROPATHY; POLYNEUROPATHY; PRIMARY PREVENTION; QT PROLONGATION; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SEIZURE; SIDE EFFECT; SKIN ALLERGY; SOUTH AND CENTRAL AMERICA; THROMBUS; WEIGHT REDUCTION;

BRAIN ISCHEMIA; CARDIOMYOPATHIES; CHAGAS CARDIOMYOPATHY; CHAGAS DISEASE; HUMANS; PROGNOSIS; RISK FACTORS; STROKE; TRYPANOCIDAL AGENTS; TRYPANOSOMA; TRYPANOSOMIASIS, AFRICAN;

EID: 77952168824     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.33     Document Type: Review

References (98)

1. Carod-Artal FJ. Trypanosomiasis. In: International Neurology, A Clinical Approach (1st Edition). Lisak R, Truong D, Carroll W, Bhidayasiri R (Eds). John Wiley & Sons, Oxford, UK, 290-292 (2009).
2. Moncayo A, Silveira AC. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem. Inst. Oswaldo Cruz 104(Suppl. 1), 17-30 (2009).
3. Mathers CD, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl. Trop. Dis. 1, e114 (2007).
4. Carod-Artal FJ. Stroke in central nervous system infections. Ann. Indian Acad. Neurol. 11, 64-78 (2008).
5. Araujo A, Jansen AM, Reinhard K, Ferreira LF. Paleoparasitology of Chagas disease - a review. Mem. Inst. Oswaldo Cruz 104(Suppl. 1), 9-16 (2009).
6. WHO. Global burden of disease estimates: 2004 update. WHO, Geneva, Switzerland (2008).
7. Carod-Artal FJ. Strokes caused by infection in the tropics. Rev. Neurol. 44(12), 755-763 (2007).
8. Schofield CJ, Dias JC. The Southern Cone Initiative against Chagas disease. Adv. Parasitol. 42, 1-27 (1999).
9. Guhl F, Pinto N, Aguilera G. Sylvatic triatominae: a new challenge in vector control transmission. Mem. Inst. Oswaldo Cruz 104(Suppl. 1), 71-75 (2009).
10. Carod Artal FJ. Bolivia. In: Mosby's Pocket Guide to Cultural Health Assessment (4th Edition). D'Avanzo C (Ed.). 83-88 (2008).
11. Higo H, Miura S, Horio M et al. Genotypic variation among lineages of Trypanosoma cruzi and its geographic aspects. Parasitol. Int. 53, 337-344 (2004).
12. Sánchez Negrete O, Mora MC, Basombrío MA. High prevalence of congenital Trypanosoma cruzi infection and family clustering in Salta, Argentina. Pediatrics 115, 668-672 (2005).
13. Nóbrega AA, Garcia MH, Tatto E et al. Oral transmission of Chagas disease by consumption of açaí palm fruit, Brazil. Emerg. Infect. Dis. 15, 653-655 (2009).
14. Valente SA, da Costa Valente V, das Neves Pinto AY et al. Analysis of an acute Chagas disease outbreak in the Brazilian Amazon: human cases, triatomines, reservoir mammals and parasites. Trans. R. Soc. Trop. Med. Hyg. 103, 291-297 (2009).
15. Schmunis GA, Yadon ZE. Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop. DOI: 10.1016/j. actatropica.2009.11. 003 (2009) (Epub ahead of print).
16. Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin. Infect. Dis. 49, e52-e54 (2009).
17. Milei J, Guerri-Guttenberg RA, Grana DR, et al. Prognostic impact of Chagas disease in the United States. Am. Heart. J. 157, 22-29 (2009).
18. Hanford EJ, Zhan FB, Lu Y, Giodano A. Chagas disease in Texas: recognizing the significance and implications of evidence in the literature. Soc. Sci. Med. 65, 60-79 (2007).
19. Bowling J, Walter EA. Recognizing and meeting the challenge of Chagas disease in the USA. Expert Rev. Anti. Infect. Ther. 7(10), 1223-1234 (2009).
20. Yadon ZE, Schmunis GA. Congenital Chagas disease: estimating the potential risk in the United States. Am. J. Trop. Med. Hyg. 81(6), 927-933 (2009).
21. Piron M, Vergés M, Muñoz J et al. Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion 48, 1862-1868 (2008).
22. Muñoz J, Coll O, Juncosa T et al. Prevalence and vertical transmission of Trypanosoma cruzi infection among pregnant Latin American women attending 2 maternity clinics in Barcelona, Spain. Clin. Infect. Dis. 48(12), 1736-1740 (2009).
23. Martinez de Tejada B, Jackson Y, Paccolat C, Irion O; Groupe Chagas Congénital Genéve. Congenital Chagas disease in Geneva: diagnostic and clinical aspects. Rev. Med. Suisse 5, 2094-2096 (2009).
24. Barr SC. Canine Chagas' disease (American trypanosomiasis) in North America. Vet. Clin. North Am. Small Anim. Pract. 39, 1055-1064 (2009).
25. No authors listed. Chagas disease: the forgotten American neuroinfection. Lancet Neurol. 8, 501 (2009).
26. Otani MM, Vinelli E, Kirchhoff LV et al. WHO comparative evaluation of serologic assays for Chagas disease. Transfusion 49, 1076-1082 (2009).
27. Benvenuti LA, Roggério A, Freitas HF, Mansur AJ, Fiorelli A, Higuchi ML. Chronic American trypanosomiasis: parasite persistence in endomyocardial biopsies is associated with high-grade myocarditis. Ann. Trop. Med. Parasitol. 102, 481-487 (2008).
28. Lewis MD, Ma J, Yeo M, Carrasco HJ, Llewellyn MS, Miles MA. Genotyping of Trypanosoma cruzi: systematic selection of assays allowing rapid and accurate discrimination of all known lineages. Am. J. Trop. Med. Hyg. 81, 1041-1049 (2009).
29. Rassi A Jr, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease. A systematic review of observational studies. Circulation 115, 1101-1108 (2007).
30. Rassi A Jr, Rassi A, Little WC et al. Development and validation of a risk for predicting mortality in Chagas' heart disease. N. Engl. J. Med. 355, 799-808 (2006).
31. Carod-Artal FJ. Chagas cardiomyopathy and ischemic stroke. Expert Rev. Cardiovasc. Ther. 4(1), 119-130 (2006).
32. Davila DF, Rossell RO, Donis JH. Cardiac parasympathetic abnormalities: cause or consequence of Chagas heart disease. Parasitol. Today 5, 327-329 (1989).
33. Rossi MA, Ramos SG. Coronary microvascular abnormalities in Chagas' disease. Am. Heart. J. 132, 207-210 (1996).
34. Marin-Neto JA, Cunha-Neto E, Maciel BC et al. Pathogenesis of chronic Chagas heart disease. Circulation 115, 1109-1123 (2007).
35. Elias FE, Vigliano CA, Laguens RP, Levin MJ, Berek C. Analysis of the presence of Trypanosoma cruzi in the heart tissue of three patients with chronic Chagas' heart disease. Am. J. Trop. Med. Hyg. 68, 242-247 (2003).
36. Carod Artal FJ, Vargas AP, Melo M, Horan T. American trypanosomiasis (Chagas' disease): an unrecognized cause of stroke. J. Neurol. Neurosurg. Psychiatry 74, 516-518 (2003).
37. Leon-Sarmiento FE, Mendoza E, Torres-Hillera M et al. Trypanosoma cruzi-associated cerebrovascular disease: a case-control study in Eastern Colombia. J. Neurol. Sci. 217, 61-64 (2004).
38. Carod-Artal FJ. Stroke: a neglected complication of American trypanosomiasis (Chagas' disease). Trans. R. Soc. Trop. Med. Hyg. 101, 1075-1080 (2007).
39. Del Brutto OH, Carod-Artal FJ, Román GC et al. Stroke in the tropics. In: Tropical Neurology. American Academy of Neurology (Ed.). Lippincott Williams & Wilkins, PA, USA, 11-35 (2002).
40. Pittella JE. Central nervous system involvement in Chagas disease: a hundred-year-old history. Trans. R. Soc. Trop. Med. Hyg. 103, 973-978 (2009).
41. Aras R, da Matta JAM, Mota G, Gomes I, Melo A. Cerebral infarction in autopsies of chagasic patients with heart failure. Arq. Bras. Cardiol. 81, 414-416 (2003).
42. Oliveira-Filho J, Viana LC, Vieira de Melo RM et al. Chagas disease is an independent risk factor for stroke: baseline characteristics of a chagas disease cohort. Stroke 36, 2015-2017 (2005).
43. Paixão LC, Ribeiro AL, Valacio RA et al. Chagas disease. Independent risk factor for stroke. Stroke 40(12), 3691-3694 (2009).
44. Bestetti R. Stroke in a hospital-derived cohort of patients with chronic Chagas' disease. Acta Cardiol. 55, 33-38 (2000).
45. Nunes MCP, Barbosa MM, Ribeiro ALP, Barbosa FBL, Rocha MOC. Ischemic cerebrovascular events in patients with Chagas cardiomyopathy: a prospective follow-up study. J. Neurol. Sci. 278, 96-101 (2009).
46. Carod-Artal FJ, Ribeiro Lda S, Vargas AP. Awareness of stroke risk in chagasic stroke patients. J. Neurol. Sci. 263, 35-39 (2007).
47. Viotti RJ, Vigliano C, Laucella S et al. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart 90, 655-660 (2004).
48. Oliveira JSM, Araujo RLC, Navarro MA et al. Cardiac thrombosis and thromboembolism in chronic Chagas' heart disease. Am. J. Cardiol. 2, 147-151 (1983).
49. Carod-Artal FJ, Vargas AP, Horan TA, Nunes LG. Chagasic cardiomyopathy is independently associated with ischemic stroke in Chagas disease. Stroke 36, 965-970 (2005).
50. Carod-Artal FJ, Horan TA, Vargas AP, Ribeiro LS, Mamare EM. Cardioembolic stroke and ischemic small bowel infarction in a Chagas' disease patient. Eur. J. Neurol. 14, e8 (2007).
51. Carod-Artal FJ, Melo M, Vargas AP. Ictus cardioembólico en la enfermedad de Chagas. Rev. Neurol. 33, 311-315 (2001).
52. Carod-Artal FJ, Vargas AP, Melo M et al. Síndrome de la oclusión rostral de la arteria basilar y enfermedad de Chagas. Rev. Neurol. 35, 337-341 (2002).
53. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in the Framingham Heart Study subjects. Circulation 88, 107-115 (1993).
54. Viotti R, Vigliano CA, Alvarez MG et al. The impact of socioeconomic conditions on chronic Chagas disease progression. Rev. Esp. Cardiol. 62, 1224-1232 (2009).
55. Wackermann PV, Franca Fernandes RM, Elias J Jr et al. Involvement of the central nervous system in the chronic form of Chagas' disease. J. Neurol. Sciences 269, 152-157 (2008).
56. Oliveira-Filho J, Vieira de Melo RM, Reis PSO et al. Chagas disease is independently associated with brain atrophy. J. Neurol. 256, 1363-1365 (2009).
57. Lima-Costa NF, Castro-Costa E, Uchoa E et al. A population-based study of the association between Trypanosoma cruzi infection and cognitive impairment in old age (the Bambuí study). Neuroepidemiology 32, 122-128 (2009).
58. Villar JC, Marin-Neto JA, Ebrahim S, Yusuf S. Trypanocide therapy for chronic asymptomatic Trypanosoma cruzi infection: a systematic review. Cochrane Database Syst. Rev. 1, CD 003463 (2002).
59. Bern C, Montgomery SP, Herwaldt BL et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 298, 2171-2181 (2009).
60. Castro JA, Montalto de Mecca M, Bartel LC. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum. Exp. Toxicol. 25, 471-479 (2006).
61. Viotti R, Vigliano C, Lococo B et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev. Anti. Infect. Ther. 7(2), 157-163 (2009).
62. Garcia-Bournissen F, Altcheh J, Panchaud A, Ito S. Is use of nifurtimox for the treatment of Chagas disease compatible with breastfeeding? A population pharmacokinetics analysis. Arch. Dis. Child. 95(3), 224-228 (2010).
63. Ribeiro I, Sevcsik AM, Alves F et al. New, improved treatments for Chagas disease: from the R&D pipeline to the patients. PLoS Negl. Trop. Dis. 3, e484 (2009).
64. Buckner FS. Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. Adv. Exp. Med. Biol. 625, 61-80 (2008).
65. Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop. DOI: 10.1016/j.actatropica.2009.10. 023 (2009) (Epub ahead of print).
66. Garcia S, Ramos CO, Senra JFV et al. Treatment with benznidazole during the chronic phase of experimental Chagas disease decreases cardiac alterations. Antimicrob. Agents Chemother. 49, 1521-1528 (2005).
67. Viotti R, Vigliano C. Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidence-based medicine. Expert Rev. Anti. Infect. Ther. 5(4), 717-726 (2007).
68. Sosa-Estani S, Segura EL. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr. Opin. Infect. Dis. 19, 583-587 (2006).
69. Viotti R, Vigliano C, Lococo B et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann. Intern. Med. 144, 724-734 (2006).
70. Reyes PA, Vallejo M. Trypanocide drugs for the late stage, symptomatic CD (Trypanosoma cruzi infection). Cochrane Database Syst. Rev. 4, CD004102 (2005).
71. Marin-Neto JA, Rassi A, Morillo CA et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the benznidazole evaluation for interrupting trypanosomiais (BENEFIT). Am. Heart J. 156, 37-43 (2008).
72. Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 37, 577-617 (2006).
73. Derex L, Nighoghossian N, Perinetti M, Honnorat J, Trouillas P. Thrombolytic therapy in acute ischemic stroke patients with cardiac thrombus. Neurology 57, 2122-2125 (2001). (Pubitemid 33126887)
74. Trabuco CC, Pereira de Jesus PA, Bacellar AS, Oliveira-Filho J. Successful thrombolysis in cardioembolic stroke from Chagas disease. Neurology 62, 170-171 (2005).
75. Dubner S, Schapachnik E, Riera AR, Valero E. Chagas disease: state-of-the-art of diagnosis and management. Cardiol. J. 15, 493-504 (2008).
76. Carod-Artal FJ. Some reflections on stroke treatment in South America. Rev. Neurol. 44, 257-258 (2007).
77. Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet 375(9709), 148-159 (2009).
78. Smith DH, Pepin J, Stich AHR. Human African trypanosomiasis: an emerging public health crisis. Br. Med. J. 54, 341-355 (1998).
79. WHO. Human African trypanosomiasis (sleeping sickness): epidemiological update. Wkly Epidemiol. Rec. 8, 71-80 (2006).
80. Lejon V, Boelaert M, Jannin J, Moore A, Buscher P. The challenge of Trypanosoma brucei gambiense sleeping sickness outside Africa. Lancet Infect. Dis. 3, 804-808 (2003).
81. Jelinek T, Bisoffi Z, Bonazzi L et al. Cluster of African trypanosomiasis in travelers to Tanzanian national parks. Emerg. Infect. Dis. 8, 634-635 (2002).
82. Moore AC, Ryan ET, Waldron MA. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 20-2002. A 37-year-old man with fever, hepatosplenomegaly, and a cutaneous foot lesion after a trip to Africa. N. Engl. J. Med. 346, 2069-2076 (2002).
83. Blum J, Schmid C, Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop. 97, 55-64 (2006).
84. Kennedy PG. Human African trypanosomiasis: neurological aspects. J. Neurol. 253, 411-416 (2006).
85. Blum JA, Zellweger MJ, Burri C, Hatz C. Cardiac involvement in African and American trypanosomiasis. Lancet Infect. Dis. 8, 631-641 (2008).
86. Blum JA, Burri C, Hatz C, Kazumba L, Mangoni P, Zellweger MJ. Sleeping hearts: the role of the heart in sleeping sickness (human African tryopanosomiasis). Trop. Med. Int. Health 12, 1422-1432 (2007).
87. Poltera AA, Hochmann A, Lambert PH. A model for cardiopathy induced by Trypanosoma brucei brucei in mice. A histologic and immunopathologic study. Am. J. Pathol. 99, 325-352 (1980). (Pubitemid 10116229)
88. Collomb H, Bartoli D. The heart in human African trypanosomiasis caused by Trypanosoma gambiense. Bull. Soc. Pathol. Exot. Filiales 60, 142-156 (1967).
89. Blum JA, Schmid C, Burri C et al. Cardiac alterations in Human African Trypanosomiasis (T.b. gambiense) with respect to the disease stage and antiparasitic treatment. PLoS Negl. Trop. Dis. 3, e383 (2009).
90. Damian MS, Dorndof W, Burkardt H, Singer I, Leinweber B, Schachenmayr W. Polyneuritis and myositis in Trypanosoma gambiense infection. Dtsch Med. Wochenschr. 119, 1690-1693 (1994).
91. Croft AM, Jackson CJ, Friend HM, Minton EJ. African trypanosomiasis in a British soldier. J. R. Army Med. Corps 152, 156-160 (2006).
92. Tsala MP, Blackett K, Mbonifor CL, Leke R, Etoundi J. Functional and immunologic involvement in human African tryopanosomiasis caused by Trypanosoma gambiense. Bull. Soc. Pathol. Exot. Filiales 81, 490-501 (1988).
93. Barrett MP, Boykin DW, Brun R, Tidwell RR. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br. J. Pharmacol. 152, 1155-1171 (2007).
94. Priotto G, Pinoges L, Fursa IB et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. Br. Med. J. 336, 679-680 (2008).
95. Blum J, Nkunku S, Burri C. Clinical description of encephalophathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop. Med. Int. Health 6, 390-400 (2001).
96. Chappuis F. Melarsoprol-free drug combinations for second stage Gambian sleeping sickness: the way to go. Clin. Infect. Dis. 45, 1443-1445 (2007).
97. Priotto G, Kasparian S, Mutombo W et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, Phase III, non-inferiority trial. Lancet 374, 56-64 (2009).
98. Carod-Artal FJ. Chagas disease and stroke. Lancet Neurol. 9, 533-542 (2010).